Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,057.50    -61.50 (-5.50%)
Bid:
1,057.00
Ask:
1,058.00
Spread: 1.00 (0.095%)
Market Cap: £3.39b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Statement

8 Nov 2017 07:00

RNS Number : 8289V
Persimmon PLC
08 November 2017
 

 

THIRD QUARTER TRADING STATEMENT

 

WEDNESDAY 8 NOVEMBER 2017

 

Persimmon plc today releases its third quarter Trading Statement which covers the period from 1 July 2017 to 7 November 2017.

 

Customer activity has strengthened in line with traditional seasonality as we have moved from the quieter summer weeks into the autumn period. Consumer confidence is resilient and mortgage lenders remain keen to compete for new business, with mortgage approvals for the third quarter being c. 8% ahead of last year. Mortgage interest rates remain very attractive, particularly for first time buyers taking advantage of the Government's Help to Buy scheme.

 

Enquiries received from customers, including website traffic, have been running in line with the elevated levels of last year despite the Group's total sales outlet numbers being c.10% lower over the autumn period to date. The level of visitor traffic to our sites has remained healthy. The Group's total sales rate per site in the period since we reported our half year results has been in line with the prior year, which was 14% ahead of 2015 due to particularly strong sales post the 2016 EU Referendum. We are now fully sold up for the current year and have c.£909 million of forward sales reserved beyond 2017, an increase of 10% on the same point last year (2016: £829 million). Pricing remains firm across our regional markets.

 

We have continued to drive site construction activities forward during the third quarter to ensure customers are able to move into their new homes in line with their expectations. We are focused on opening new sales outlets at the earliest opportunity to meet market demand. The Group continues to encounter a tight market for both key house building trade skills and some materials. The Group is actively developing all sites where an implementable detailed planning consent has been secured.

 

At this point in the cycle we remain focused on disciplined investment in high quality new land to support the delivery of superior returns and cash generation over the longer term. The National Planning Policy Framework continues to task local authorities with identifying more land to be released for development. However, achieving detailed planning consent for the land identified is proving as challenging as ever. We are keen to work with all stakeholders taking part in the Government's Housing White Paper consultations to establish more effective planning processes which will allow the industry to increase the number of active outlets and overall output of new homes built. The Group opened 95 new sales outlets in the first half of the year and has launched a further 61 through the second half to date. Management has made good progress with construction on new sites and we anticipate opening c. 45 additional sales outlets during the remainder of the year. To support the Group's future growth we plan to open a new regional operating business near Ipswich in Suffolk on 2 January 2018, bringing the number of house building businesses in the Group to thirty.

 

Management has continued to pursue new land opportunities on a selective basis. The Group acquired a total of 5,526 new plots and spent £147 million, including payment of deferred land creditors, during the period. Of the new plots acquired, 48% have been converted from our strategic land portfolio. We anticipate that the Group will achieve strong strategic land conversion over the next couple of years as local authorities complete their plans to identify sufficient land to meet the assessed housing need in their local communities. Management will marshal the Group's cash resources to ensure these reinvestment requirements are adequately supported.

 

Management remain focused on the cash efficiency of Group operations with strong cash generation being central to the execution of our long-term strategy. The Group is likely to hold increased cash balances at 31 December 2017 subject to the timing of further land investment (30 June 2017: £1,120.4 million).

 

We will give a further update on progress and trading following the year end on Tuesday 9 January 2018.

 

Jeff Fairburn and Mike Killoran will host a conference call with analysts at 9.00 a.m. today. To participate please dial +44 (0)33 3300 0804. The access pin is 72233806# and password is "Persimmon".

 

Further information, please contact:

 

Persimmon plc

Citigate Dewe Rogerson

Jeff Fairburn, Group Chief Executive

Simon Rigby

Mike Killoran, Group Finance Director

Kevin Smith

Tel: +44 (0)1904 642199

Tel: +44 (0)20 7638 9571

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBRBATMBBMBTR
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.